CytomX Therapeutics EBITDA | CTMX

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA CytomX Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-21.2 M	26.6 M	-4.48 M	-99 M	-32.3 M	-21.7 M	-139 M	-76 M	-44.6 M	-57.9 M	-32 M	-29 M	-14.3 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
26.6 M	-139 M	-41.9 M

Quarterly EBITDA CytomX Therapeutics

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-23.7 M	-19.6 M	-	-	22.7 M	-	-	11.7 M	-	-	-5.62 M	-	-29.6 M	-30.1 M	-32 M	-	-22.5 M	-19.2 M	-15.6 M	-	-14.8 M	-16.1 M	-2.76 M	-	-25.6 M	-31.2 M	-15.9 M	-25.8 M	-23.1 M	-12.5 M	-15.3 M	-	-9.78 M	-25 M	-8.22 M	-	-14.5 M	-13.8 M	-15.8 M	-	-11 M	-5.24 M	-4.6 M	-	-2.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
22.7 M	-32 M	-14.8 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	-14.4 M	-	-6.63 %	$ 13.9 M	USA
FSD Pharma HUGE	-15.3 M	-	5743.5 %	$ 69.7 M	Canada
Qilian International Holding Group Limited QLI	-11.1 M	-	-6.08 %	$ 184 M	China
Happiness Biotech Group Limited HAPP	-6.4 M	-	1.35 %	$ 17.8 M	China
Synthetic Biologics SYN	-23.9 M	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	505 K	-	-	$ 2.02 B	USA
BioXcel Therapeutics BTAI	-50.2 M	$ 1.19	5.31 %	$ 14.5 M	USA
Burford Capital Limited BUR	232 M	$ 4.37	0.23 %	$ 958 M	Britain
I-Mab IMAB	23.9 M	-	-	$ 866 M	China
BeyondSpring BYSI	-8.86 M	$ 0.84	34.27 %	$ 34.5 M	USA
Corner Growth Acquisition Corp. COOL	-1.99 M	-	-0.89 %	$ 114 M	USA
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-14.3 M	-	-13.47 %	$ 169 M	France
Cerus Corporation CERS	-7.26 M	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	31.8 M	$ 2.41	4.17 %	$ 225 M	Israel
CureVac N.V. CVAC	178 M	-	-	$ 867 M	Germany
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	-101 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	-11.9 M	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	-10.1 M	-	-	$ 4.9 B	Britain
Завод ДИОД DIOD	85.9 M	-	-	-	Russia
Galera Therapeutics GRTX	-2.54 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	-8.64 M	-	-18.52 %	$ 27.3 M	Britain
Hepion Pharmaceuticals HEPA	-4.16 M	-	-18.79 %	$ 39.3 K	USA
ARCA biopharma ABIO	-122 M	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	-252 M	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	260 K	$ 5.1	2.63 %	$ 70.5 M	USA
Affimed N.V. AFMD	-107 M	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	-100 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	-40.9 M	-	-	$ 12.5 M	Belgium
Adial Pharmaceuticals ADIL	-7.8 M	$ 3.98	1.86 %	$ 2.66 M	USA
Generation Bio Co. GBIO	-137 M	-	-	$ 344 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
AnaptysBio ANAB	48.5 M	$ 58.47	4.37 %	$ 1.68 B	USA
Anika Therapeutics ANIK	-5.68 M	$ 21.5	1.56 %	$ 308 M	USA
Cyclacel Pharmaceuticals CYCCP	-8.42 M	-	-4.36 %	$ 27 M	USA
Gracell Biotechnologies GRCL	-566 M	-	-	$ 3.37 B	China
Aurinia Pharmaceuticals AUPH	52.7 M	$ 15.47	1.91 %	$ 2.08 B	Canada
GlycoMimetics GLYC	-153 M	-	9357.83 %	$ 1.01 B	USA
Aeterna Zentaris AEZS	-10.7 M	-	5.93 %	$ 314 M	Canada
AVROBIO AVRO	-82.7 M	-	1083.1 %	$ 745 M	USA
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
Bicycle Therapeutics plc BCYC	-241 M	$ 3.9	0.24 %	$ 270 M	Britain
Beam Therapeutics BEAM	-361 M	$ 26.75	0.91 %	$ 2.65 B	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
BioMarin Pharmaceutical BMRN	489 M	$ 67.36	0.99 %	$ 12.9 B	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada